Search results
Order by most recent / most popular / relevance
Results: 1-10 of 164
Bartlett - take it up
- Dechert LLP
- -
- USA
- -
- May 2 2012
The First Circuit decided Bartlett v. v. Mutual Pharmaceutical Co., No. 10-2277, slip op. (1st Cir. May 2, 2012) today - suggesting that it is the worst court of appeals in the country for defendants in prescription pharmaceutical product cases
Darvocet plaintiffs' Hail mary batted away
- Dechert LLP
- -
- USA
- -
- April 25 2012
We’ve posted before about MDLs and the Darvocet MDL in particular being the new “heavyweight” division for the one-two punch of product identification (can’t sue non-manufacturers) and generic preemption (can't sue generic manufacturers) to dispose of meritless claims involving generic drugs on a large scale
If at first you don't succeed....
- Dechert LLP
- -
- USA
- -
- April 23 2012
Sometimes good ideas don’t prevail the first time or even the first few times they make their appearance
Pain pump plaintiff’s promotion-based punitives precluded
- Dechert LLP
- -
- USA
- -
- April 12 2012
It’s déjà vu all over again
A pro-defense decision good for the digestion
- Dechert LLP
- -
- USA
- -
- April 11 2012
As an openly defense-oriented blog, most of our posts deal with cases in which plaintiffs could not make out their claims
What a difference an MDL transfer makes
- Dechert LLP
- -
- USA
- -
- April 6 2012
Thanks to Jim Fraser at Venable for passing along a nice fraudulent misjoinder finding in the Fosamax MDL, Welsh v. Merck Sharpe & Dohme Corp., C.A. No. 11-3045, slip op. (D.N.J. April 3, 2012
GSK citizenship issue on appeal
- Dechert LLP
- -
- USA
- -
- April 6 2012
We can’t say much of substance about this issue, as we represent GlaxoSmithKline in certain matters, but a remedy is in sight (we hope) for the peculiar situation that has developed with respect to GSK’s citizenship for purposes of diversity jurisdiction
Generic drug preemption Q and A
- Dechert LLP
- -
- USA
- -
- April 5 2012
There are now forty-eight post-Mensing generic drug preemption decisions on our scorecard, with more being decided on what seems like a weekly basis
